CPHON Chemo Exam Questions With Correct
Answers
Which |Chemo |agent |is |associated |with |a |high |risk |for |hypersensitivity |reaction?
A. |Methotrexate
B. |Carboplatin
C. |Cytarabine
D. |Busulfan |- |CORRECT |ANSWER✔✔-B
Before |a |patient |is |to |receive |intrathecal |Chemo: |
A. |Ensure |developmentally |appropriate |patient |teaching |is |completed
B. |Verify |the |patient's |white |blood |cell |count
C. |Ensure |other |chemo |agents |are |available |to |administer
D. |Apply |LMX |cream |between |L5-L7 |- |CORRECT |ANSWER✔✔-A
John |is |a |3-year-old |who |is |scheduled |to |receive |his |first |subQ |injection |of |Neupogen. |What |
would |NOT |be |an |appropriate |strategy |to |decrease |the |pain |associated |with |a |SC |injection?
A. |Use |of |ice |and |insuflon |catheter
B. |Use |of |LMX |cream
C. |Use |of |distraction
D. |Use |of |buffered |lidocaine |- |CORRECT |ANSWER✔✔-D
,The |preferred |intramuscular |site |for |a |child |wo |is |three-years-old |and |walks |is:
A. |Deltoid |muscle
B. |Vastus |lateralis |muscle
C. |Ventogluteal |muscle
D. |Dorsogluteal |muscle |- |CORRECT |ANSWER✔✔-A
Which |statement |best |describes |the |nursing |assessment |for |patency |with |a |direct-push |
method |of |administering |a |chemotherapy |vesicant:
A. |Assess |for |blood |return |before |the |infusion, |every |2-5ml, |and |for |blood |return |and |pain |at |
the |end |of |the |infusion
B. |Assess |for |blood |return |before |the |infusion |and |at |the |completion |of |the |infusion
C. |Assess |for |blood |return |before |the |infusion |and |for |pain |at |the |completion |of |the |infusion
D. |Assess |for |blood |return |before |infusion, |every |5-10ml, |during |the |infusion, |and |at |the |end |
of |the |infusion |- |CORRECT |ANSWER✔✔-A
A |strategy |to |prevent |chemo |errors |includes:
A. |Verification |of |patient's |height |in |inches
B. |Independent |dose |calculation
C. |Use |of |full |trade |name |of |the |drug
D. |Use |of |abbreviations |for |drug |clarification |- |CORRECT |ANSWER✔✔-B
Which |chemo |agent |is |associated |with |a |maximum |cumulative |lifetime |dose?
A. |Cyclophosphamide |
, B. |Etoposide
C. |Daunorubicin
D. |Nitrogen |mustard |- |CORRECT |ANSWER✔✔-C
After |administering |the |first |drug |for |a |dermatologiv |reaction |after |peg-Asparaginase, |Sam |
starts |to |complain |of |throat |tightening |and |he |starts |wheezing. |The |MD |orders |Epiniphrine. |
What |is |the |preferred |route? |
A. |PO
B. |Sub-Q
C. |IV
D. |IM |- |CORRECT |ANSWER✔✔-D
You |are |giving |Doxorubicin |peripherally |IV |push |and |based |on |the |patient's |complaints |and |
loss |of |blood |return, |you |suspect |that |the |Doxorubicin |has |extravasated. |Your |immediate |
nursing |intervention |will |involve:
A. |SLAPP: |Stop |the |infusion, |leave |the |needle, |aspirate |as |much |drug |as |possible, |pull |the |
needle, |provider |notification
B. |SLAPP: |Slow |the |infusion, |leave |the |needle, |attempt |to |flush, |push |the |remainder |of |the |
flush |into |the |vein, |pull |the |needle
C. |STOP: |Stop |the |infusion, |treat |the |site, |oncology |team |notification, |provide |follow |up
D. |STOP: |Slow |the |infusion, |treat |the |symptoms, |oncology |team |notification, |provide |follow |up
|- |CORRECT |ANSWER✔✔-A
The |immediate |temperature |application |for |a |Doxorubicin/Daunorubicin |extravasation |
involves:
A. |Hot |application
Answers
Which |Chemo |agent |is |associated |with |a |high |risk |for |hypersensitivity |reaction?
A. |Methotrexate
B. |Carboplatin
C. |Cytarabine
D. |Busulfan |- |CORRECT |ANSWER✔✔-B
Before |a |patient |is |to |receive |intrathecal |Chemo: |
A. |Ensure |developmentally |appropriate |patient |teaching |is |completed
B. |Verify |the |patient's |white |blood |cell |count
C. |Ensure |other |chemo |agents |are |available |to |administer
D. |Apply |LMX |cream |between |L5-L7 |- |CORRECT |ANSWER✔✔-A
John |is |a |3-year-old |who |is |scheduled |to |receive |his |first |subQ |injection |of |Neupogen. |What |
would |NOT |be |an |appropriate |strategy |to |decrease |the |pain |associated |with |a |SC |injection?
A. |Use |of |ice |and |insuflon |catheter
B. |Use |of |LMX |cream
C. |Use |of |distraction
D. |Use |of |buffered |lidocaine |- |CORRECT |ANSWER✔✔-D
,The |preferred |intramuscular |site |for |a |child |wo |is |three-years-old |and |walks |is:
A. |Deltoid |muscle
B. |Vastus |lateralis |muscle
C. |Ventogluteal |muscle
D. |Dorsogluteal |muscle |- |CORRECT |ANSWER✔✔-A
Which |statement |best |describes |the |nursing |assessment |for |patency |with |a |direct-push |
method |of |administering |a |chemotherapy |vesicant:
A. |Assess |for |blood |return |before |the |infusion, |every |2-5ml, |and |for |blood |return |and |pain |at |
the |end |of |the |infusion
B. |Assess |for |blood |return |before |the |infusion |and |at |the |completion |of |the |infusion
C. |Assess |for |blood |return |before |the |infusion |and |for |pain |at |the |completion |of |the |infusion
D. |Assess |for |blood |return |before |infusion, |every |5-10ml, |during |the |infusion, |and |at |the |end |
of |the |infusion |- |CORRECT |ANSWER✔✔-A
A |strategy |to |prevent |chemo |errors |includes:
A. |Verification |of |patient's |height |in |inches
B. |Independent |dose |calculation
C. |Use |of |full |trade |name |of |the |drug
D. |Use |of |abbreviations |for |drug |clarification |- |CORRECT |ANSWER✔✔-B
Which |chemo |agent |is |associated |with |a |maximum |cumulative |lifetime |dose?
A. |Cyclophosphamide |
, B. |Etoposide
C. |Daunorubicin
D. |Nitrogen |mustard |- |CORRECT |ANSWER✔✔-C
After |administering |the |first |drug |for |a |dermatologiv |reaction |after |peg-Asparaginase, |Sam |
starts |to |complain |of |throat |tightening |and |he |starts |wheezing. |The |MD |orders |Epiniphrine. |
What |is |the |preferred |route? |
A. |PO
B. |Sub-Q
C. |IV
D. |IM |- |CORRECT |ANSWER✔✔-D
You |are |giving |Doxorubicin |peripherally |IV |push |and |based |on |the |patient's |complaints |and |
loss |of |blood |return, |you |suspect |that |the |Doxorubicin |has |extravasated. |Your |immediate |
nursing |intervention |will |involve:
A. |SLAPP: |Stop |the |infusion, |leave |the |needle, |aspirate |as |much |drug |as |possible, |pull |the |
needle, |provider |notification
B. |SLAPP: |Slow |the |infusion, |leave |the |needle, |attempt |to |flush, |push |the |remainder |of |the |
flush |into |the |vein, |pull |the |needle
C. |STOP: |Stop |the |infusion, |treat |the |site, |oncology |team |notification, |provide |follow |up
D. |STOP: |Slow |the |infusion, |treat |the |symptoms, |oncology |team |notification, |provide |follow |up
|- |CORRECT |ANSWER✔✔-A
The |immediate |temperature |application |for |a |Doxorubicin/Daunorubicin |extravasation |
involves:
A. |Hot |application